An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

NCT ID: NCT00823199

Last Updated: 2018-08-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-11-30
• Study Completion Date: 2008-08-31

Brief Summary

This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

Conditions

Schizophrenia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Allopurinal treatment

Allopurinal 300mg once daily by mouth for four weeks

Group Type: EXPERIMENTAL

Allopurinal

Intervention Type: DRUG

300mg once daily by mouth for four weeks

Interventions

Allopurinal

300mg once daily by mouth for four weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms)

Exclusion Criteria

• Over 65
• Renal or liver disease
• Diabetes
• Hypertension
• Taking thiazides or ACE inhibitors

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bronx Psychiatric Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Nigel Bark MD

Director Schizophrenia Research

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Nigel Bark, MD

Role: PRINCIPAL_INVESTIGATOR

Bronx Psychiatric Center

Other Identifiers

ICFV12/02

Identifier Type: -

Identifier Source: org_study_id